Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Ipsen

Status: Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Study type: Observational

Funder types: Industry

Identifiers

NCT03017690

A-US-52030-358

Details and patient eligibility

About

An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women must be 18 years of age or older
• A current diagnosis of advanced, unresectable GEP-NET
• Provided written informed consent to participate in the study
• Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA).

Exclusion criteria

• Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
• Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day
• Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment
• Known hypersensitivity to somatostatin analogues

Trial design

22 participants in 2 patient groups

lanreotide group (Somatuline Depot®)

octreotide LAR group (Sandostatin LAR®)